Anatomical and physiological connectivity of the basal ganglia-thalamocortical motor circuit by Berry, N

Heteroditopic transition metal dithiocarbamate receptors for binding cation-anion ion pairs by Berry, N, Shimell, T, Beer, P

Anion recognition as a method for templating pseudorotaxane formation. by Wisner, J, Beer, P, Berry, N, Tomapatanaget, B

Transition metal self-assembly of dithiocarbamate based anion receptors by Berry, N, Pratt, MD, Fox, O, Beer, P

Shared rhythmic subcortical GABAergic input to the entorhinal cortex and presubiculum by Viney, T, Salib, M, Joshi, A, Unal, G, Berry, N, Somogyi, P

CHAMBER: Calcium-binding proteins (calretinin, calbindin, and parvalbumin) with Nissl staining on parasagittal sections of mouse brain by Nakamura, K, Micklem, B, Berry, N, Spagnol, G, Sharott, A, Magill, P

Self-assembled dithiocarbamate-copper(II) macrocycles for electrochemical anion recognition by Beer, P, Berry, N, Drew, M, Fox, O, Padilla-Tosta, M, Patell, S

Metal-directed self-assembly of bimetallic dithiocarbamate transition metal cryptands and their binding capabilities. by Beer, P, Berry, N, Cowley, A, Hayes, E, Oates, E, Wong, W

Estimating aboveground biomass in forest and oil palm plantation in Sabah, Malaysian Borneo using ALOS PALSAR data by Morel, A, Saatchi, S, Malhi, Y, Berry, N, Banin, L, Burslem, D, Nilus, R, Ong, R

P16-38. Transient loss of intestinal CD4+CCR5+ lymphocytes following vaccination with live attenuated SIV indicates modification of T cell repertoire/memory by Elsley W, Ham C, Ferguson D, Page M, Berry N, Stebbings R, Li B, Hall J, Almond N

Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. by de Silva, T, Aasa-Chapman, M, Cotten, M, Hué, S, Robinson, J, Bibollet-Ruche, F, Sarge-Njie, R, Berry, N, Jaye, A, Aaby, P, Whittle, H, Rowland-Jones, S, Weiss, R

Intra-dermal immunisation with SIV gag-based vaccines alone inhibits acquisition of SIVmac251 by Almond N, Stebbings R, Page M, Li B, Berry N, Ham C, Ferguson D, Rose N, Mee E, Stahl-Hennig C, Dickson G, Athanasapoulos T, Benlahrech A, Herath S, Meiser A, Patterson S

Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge. by Wade-Evans, A, Stott, J, Hanke, T, Stebbings, R, Berry, N, Lines, J, Sangster, R, Silvera, P, Walker, B, MacManus, S, Davis, G, Cowie, J, Arnold, C, Hull, R, Almond, N

P03-08. Protection against SIVmac239 challenge in a rhesus macaque model conferred by a doxycycline dependent attenuated SIVmac239 by Cranage M, Stebbings R, Manoussaka M, Li B, Klaver B, Kleibeuker W, Das A, Tudor H, Elsley W, Quartey-Papafio R, Robinson M, Berry N, Page M, Berkhout B, Almond N

CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. by Stebbings, R, Berry, N, Waldmann, H, Bird, P, Hale, G, Stott, J, North, D, Hull, R, Hall, J, Lines, J, Brown, S, D'Arcy, N, Davis, L, Elsley, W, Edwards, C, Ferguson, D, Allen, J, Almond, N

Novel vaccine and gene therapy approaches against HIV-AIDS by Manoussaka M, Li B, Elsley W, Quartey-Papafio R, Robinson M, Page M, Tudor H, Berry N, Legrand N, Centlivre M, ter Brake O, Liu YP, von Eije K, Klaver B, Kleibeuker W, Das A, Stebbings R, Cranage M, Almond N, Berkhout B

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, ad... by PRINCIPLE Trial Collaborative Group, Butler, CC, Dorward, J, Yu, L-M, Gbinigie, O, Hayward, G, Saville, BR, Van Hecke, O, Berry, N, Detry, M, Saunders, C, Fitzgerald, M, Harris, V, Patel, MG, De Lusignan, S, Ogburn, E, Evans, PH, Thomas, NPB, Hobbs, FDR

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform... by Butler, CC, Yu, L-M, Dorward, J, Gbinigie, O, Hayward, G, Saville, BR, Van Hecke, O, Berry, N, Detry, MA, Saunders, C, Fitzgerald, M, Harris, V, Djukanovic, R, Gadola, S, Kirkpatrick, J, Ogburn, E, Patel, MG, de Lusignan, S, Evans, PH, Thomas, NPB, Hobbs, FDR

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial by Dorward, J, Yu, L-M, Hayward, G, Saville, B, Gbinigie, OA, van Hecke, O, Ogburn, E, Evans, PH, Thomas, N, Patel, M, Richards, DB, Berry, N, Saunders, CT, Detry, MA, Fitzgerald, M, Harris, V, Shanyinde, M, de Lusignan, S, Andersson, MI, Butler, CC, Hobbs, FDR

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial by Yu, L-M, Bafadhel, M, Dorward, JJ, Hayward, G, Saville, BR, Gbinigie, O, Van Hecke, O, Ogburn, E, Evans, PH, Thomas, NPB, Patel, MG, Richards, D, Berry, N, Detry, MA, Saunders, C, Fitzgerald, M, Harris, V, Shanyinde, M, de Lusignan, S, Andersson, MI, Barnes, PJ, Russell, REK, Nicolau, DV, Ramakrishnan, S, Hobbs, FDR, Butler, CC, Yu, L-M, Bafadhel, M, Dorward, J, Hayward, G, Saville, BR, Gbinigie, O, van Hecke, O, Ogburn, E, Evans, PH, Thomas, NPB, Patel, MG, Richards, D, Berry, N, Detry, MA, Saunders, CT, Fitzgerald, M, Harris, V, Shanyinde, M, de Lusignan, S, Andersson, MI, Barnes, PJ, Russell, REK, Nicolau, DV, Ramakrishnan, S